IC50 shift determination for mitragynine towards CYP2C9 activity in HLM without NADPH CSV JSON

In Vitro Enzyme Inhibition Experiment

IC50 shift determination for mitragynine towards CYP2C9 activity in HLM without NADPH

Inhibition was detected.  Cutoff used —

IC50<10 µM for reversible inhibition and IC50shift 1.5 fold for time dependent inhibition

diclofenac 1124300

mitragynine

4'-hydroxydiclofenac

  • CYP2C9 4309227

Cell fraction Pooled human liver microsomes -7999662

Results

Sample Compound measured Value Measurement Study sequence Additional information N replicates

Experimental Conditions

A cocktail of probe substrates for CYP2C9 (diclofenac), CYP2D6 (dextromethorphan), and CYP3A (midazolam) was used for the IC50shift determination.
Methanol (0.8 % v/v) served as solvent control. Tienilic acid (0.4 and 0.8 µM), paroxetine (0.25 and 0.5 µM), and 6',7'-dihydroxybergamottin (1 and 2 µM) served as positive control inhibitors of CYP2C9, CYP2D6, and CYP3A activities, respectively.

NA

0.05 mg/mL

Commercially available

1010191

NADPH

Available

Available

4 µM

250 µL

30 min

NADPH with no precipitant

200 µL

10 min

No dilution

0.015 - 100 µM

IC50 Shift Related Experiment